Is Virta Health Legit? What the Research Shows

Virta Health is a real telehealth company with a growing body of peer-reviewed research behind its core offering: a supervised ketogenic diet program aimed at reversing type 2 diabetes and managing prediabetes. The company has published clinical outcomes in legitimate medical journals, and the results are genuinely promising for blood sugar control, weight loss, and medication reduction. That said, the evidence comes with caveats that matter, including the absence of a randomized controlled trial and the fact that most studies are funded by the company itself.

How the Program Works

Virta pairs a very-low-carbohydrate diet (typically under 30 grams of total carbs per day) with continuous remote monitoring by a care team that includes physicians and health coaches. You track your blood sugar, ketone levels, and weight through an app, and the medical team adjusts your diabetes medications in real time as your numbers change. The goal is to get your body into a state called nutritional ketosis, where it burns fat for fuel instead of glucose, and then to keep you there long enough for metabolic improvements to take hold.

This is not a passive diet app. The medical supervision component is central to how Virta differentiates itself. Because the carbohydrate restriction can rapidly lower blood sugar, people on insulin or sulfonylureas risk dangerous lows if medications are not adjusted quickly. Virta’s physicians handle that medication management remotely, which is a meaningful safety feature and also one of the program’s headline selling points: many participants are able to reduce or eliminate diabetes medications entirely.

Blood Sugar and Diabetes Outcomes

The flagship evidence behind Virta comes from a non-randomized trial conducted at Indiana University Health. At one year, participants in the program saw clinically meaningful drops in HbA1c (the standard measure of long-term blood sugar control) and about a quarter achieved diabetes remission, defined as an HbA1c below the diabetes threshold without diabetes medications. At two years, roughly 18% still met that remission definition, a decline that reflects both some metabolic rebound and the difficulty of strict dietary adherence over time.¹

A separate observational study in U.S. military veterans showed HbA1c reductions of about 0.8 percentage points sustained at both two and three years, alongside roughly 9% body weight loss at both time points. Diabetes medication use also fell. Among the 640 veterans who enrolled, about half were still actively engaged at two years and a third at three years. Even veterans who dropped out before the two-year mark showed metabolic improvements, particularly if they had stayed enrolled for at least six months.²

What the Five-Year Data Shows

Long-term data is the make-or-break question for any diet-based intervention, and Virta has begun publishing results out to five years. In adults with prediabetes, a five-year follow-up found that participants lost an average of about 5.8 kilograms (roughly 5.3% of body weight) and maintained that loss. More striking, over half achieved normoglycemia (normal blood sugar) at some point during the five years, while only about 12% progressed to full type 2 diabetes. At the final follow-up, 22% of remaining participants had normal blood sugar. Fasting insulin, triglycerides, and inflammatory markers stayed at or below baseline levels, though those improvements did not reach statistical significance after adjustment.³

A parallel five-year study in people who already had type 2 diabetes reported durable improvements in sleep quality, pain, and mood among those who were symptomatic at baseline.⁴ These are patient-reported outcomes rather than hard biomarker endpoints, but they address a real concern: even if the numbers on a lab report look good, does the person actually feel better day to day? The data suggests yes, at least for those who stick with the program.

The critical caveat with both five-year datasets is attrition. Only 47% of the prediabetes cohort completed the five-year follow-up, meaning the results describe the people who stayed, not the full original group. The participants who dropped out may have had worse outcomes, and we have no way to know for certain.³

Retention and Dropout Rates

No dietary intervention works for everyone, and the retention numbers matter as much as the clinical results. In the veterans study, enrollment dropped from 640 to 310 at two years and to 197 at three years, a pattern of roughly 50% and 67% attrition over that span.² That is not unusual for a sustained dietary change, but it tempers the headline results. If you are considering Virta, it is worth knowing that roughly half of participants in published studies did not complete two full years.

Virta has reported higher retention in some of its own trials. In the prediabetes cohort, one- and two-year retention was 80% and 75%, respectively, which compares favorably to the real-world retention rates seen in the National Diabetes Prevention Program. Whether that difference reflects the intensity of Virta’s remote monitoring, self-selection of motivated participants, or some combination is impossible to separate without a randomized design.

Safety and Side Effects

One-year safety data from the Indiana University Health trial found no cases of metabolic acidosis, which is the primary concern people raise about ketogenic diets in people with diabetes. Acid-base physiology remained normal throughout. Uric acid levels rose transiently in the first few months but returned to baseline by one year, and no new gout cases were diagnosed. Kidney function was stable: only one participant out of 262 starters had a clinically significant rise in creatinine.⁵

Serious adverse events in the trial included two cardiac events, two cancer diagnoses, one death from renal hemorrhage, and one hypoglycemia episode following a car accident (in a patient not taking insulin as prescribed). None of these were attributed to the intervention by study investigators. Two participants developed subclinical hypothyroidism. Thyroid function is something to monitor during sustained ketosis, though the clinical significance of these cases was minor.⁵

The Cholesterol Question

LDL cholesterol is the most contentious issue surrounding ketogenic diets. In Virta’s two-year data, total LDL-C did go up in the treatment group. But the composition of those LDL particles shifted in a direction most lipid researchers consider favorable: small, dense LDL particles (the type most strongly linked to arterial plaque) dropped by 23%, while large, buoyant LDL particles increased by 29%. Nearly half of participants reversed out of the small-particle-dominant pattern that is characteristic of type 2 diabetes. Total LDL particle count and ApoB, a protein marker that tracks the number of potentially harmful particles in circulation, did not change.⁶

Carotid artery wall thickness, measured by ultrasound as a proxy for early atherosclerosis, showed no change in either the treatment or control group over two years.⁶ That is reassuring for the medium term, though two years is a short window for cardiovascular outcomes. If you or your doctor are concerned about rising LDL on a ketogenic diet, the particle-size data provides some context, but it does not fully settle the question. Cardiologists remain split on how much weight to give particle size versus total LDL-C, and long-term cardiovascular outcome studies for Virta’s approach simply do not exist yet.

Kidney Function

A common worry about high-protein and ketogenic diets is kidney damage, especially in people with diabetes who are already at higher risk for kidney disease. A post-hoc analysis of Virta participants found that kidney filtration rates (eGFR) actually improved slightly in the treatment group, gaining about 0.91 mL/min per year, while the usual-care group declined by 0.68 mL/min per year. Higher ketone levels were independently associated with greater kidney function improvement, and the benefit was most pronounced in participants who started with mildly reduced kidney function.⁷

This does not mean a ketogenic diet is inherently kidney-protective, and the analysis was a post-hoc look rather than a pre-specified outcome, which means the finding should be treated as hypothesis-generating rather than definitive. But for people worried that Virta’s diet might wreck their kidneys, the available evidence points in the opposite direction.

Mental Health and Joint Pain

Depressive symptoms dropped significantly during the first ten weeks of the program and stayed lower through two years. Mean scores on a standard depression questionnaire fell from about 9.4 at baseline to around 7.0 at ten weeks, then held relatively steady at 7.3 and 7.7 at one and two years.⁸ That early improvement likely reflects the combination of weight loss, better blood sugar control, and the psychological boost of feeling in control of a chronic condition. Whether the sustained improvement is specifically attributable to ketosis, to the coaching and accountability, or to the metabolic changes more broadly is hard to untangle.

Knee pain also improved substantially. Among participants who started with knee pain, total knee function scores improved by about 10 points at one year and held at that level through two years, while the usual-care group showed slight declines. Roughly 46% of program participants met the threshold for a clinically meaningful improvement in knee function at two years, compared to about 15% in usual care. Reductions in inflammation markers were associated with the knee improvements, suggesting the effect was not purely from weight being taken off the joints.⁹

The Limits of the Evidence

The single biggest limitation across Virta’s published research is study design. The flagship trial is non-randomized and open-label, meaning participants chose whether to join the Virta program or receive usual care. People who opt into a demanding dietary intervention are more motivated at baseline than those who do not, and that self-selection bias could inflate the apparent benefits. A true randomized controlled trial, where participants are assigned to Virta or a control condition by chance, has not been conducted for the company’s full program. That is a meaningful gap.

Nearly all of the published studies have been funded by Virta Health, and many of the authors are employees or have equity in the company. Industry funding does not automatically invalidate research. Pharmaceutical companies fund most drug trials, and the results are published in the same journals. But independent replication by researchers without a financial stake would significantly strengthen the case. As of now, the veterans study is the closest thing to an independent evaluation, conducted through a VA partnership with a somewhat different population.²

Another limitation is that the comparator in most Virta studies is “usual care,” which often means standard doctor visits and dietary advice, not an active, well-structured alternative intervention. We do not know how Virta stacks up against, say, an equally intensive Mediterranean diet program with the same level of coaching and remote monitoring. The question is not just whether cutting carbs works better than doing nothing; it is whether this particular package of carb restriction plus coaching is better than other well-supported approaches delivered with equal intensity.

Cost, Insurance, and Employer Programs

Virta’s pricing model has shifted over the years. The company works primarily through employer and health plan partnerships, meaning your access and out-of-pocket cost depend heavily on whether your employer or insurer has contracted with Virta. For individuals paying out of pocket, the cost has historically run several hundred dollars per month, which puts it in line with other medically supervised weight loss programs but well above the cost of simply following a ketogenic diet on your own.

From the employer’s perspective, cost-effectiveness modeling suggests meaningful savings that scale with the severity of obesity at enrollment. Estimated annual per-person savings ranged from about $990 for someone starting at a BMI of 30-32 up to roughly $3,500 for someone starting above a BMI of 40, driven primarily by reduced medication costs and fewer obesity-related medical events.¹⁰ These are modeled estimates rather than observed savings from a controlled study, so they should be taken as directional rather than precise.

Bone and Muscle Concerns

Two common worries about long-term ketogenic dieting are bone density loss and muscle wasting, both of which matter especially to older adults with diabetes. A systematic review of ketogenic diets and bone health found no significant changes in bone mineral density, bone resorption, or bone formation markers in people following a ketogenic diet. In women who lost 10% or more of body weight, bone resorption increased and new bone formation decreased, but without reaching a threshold that increased osteoporosis risk.¹¹

On muscle preservation, early analyses suggest that high adherence to nutritional ketosis may help people hold onto lean body mass during weight loss, which is unusual for a calorie-restricted approach. The proposed mechanism involves ketone bodies providing an alternative fuel that spares muscle protein breakdown, though this idea remains preliminary. Researchers have called for more rigorous studies to confirm whether this effect is real and to understand how it compares with the lean-mass protection offered by resistance training or higher protein intake alone.¹²

Who Virta Is and Is Not Designed For

Virta’s published evidence is strongest for people with type 2 diabetes and prediabetes. The program is built around medical supervision of carbohydrate restriction in people who are on diabetes medications, and the care model revolves around adjusting those medications safely as blood sugar drops. If you have type 2 diabetes, are on insulin or other glucose-lowering drugs, and are interested in a dietary approach, Virta’s medical management component genuinely addresses a real gap that most diet programs ignore.

The program is less clearly suited for people with type 1 diabetes (where the risk of ketoacidosis is much higher), people with a history of eating disorders (strict carb counting can be triggering), or people who need a more flexible dietary framework to sustain changes. Virta requires eating under 30 grams of carbohydrates daily, which means eliminating bread, rice, fruit, most legumes, and many vegetables. That level of restriction is manageable for some people and intolerable for others, and the retention data confirms this split.

If you are exploring Virta specifically to get off diabetes medications, the evidence supports that as a realistic goal for a meaningful fraction of participants. If you are looking at it purely for weight loss without a diabetes diagnosis, the published research is thinner, and the cost-to-benefit calculation shifts. Plenty of less expensive and less restrictive dietary approaches produce similar weight loss in people without metabolic disease. Virta’s real competitive advantage is the integration of aggressive carbohydrate restriction with medical oversight of medication changes, a combination that matters most when those medications are in play.